In every area of cancer treatment, there are specific therapeutic targets. The adverse event profile of any therapy is not well established. As more patients are treated with a developing therapy, it becomes obvious that we need to “keep our eyes wide open” to whatever CV events are possible. Once these are understood, strategies to identify these toxicities as well as optimal treatment strategies need to be devised. Drs. Mike Fradley and Joerg Herrmann explain.